Open AccessPharmacoeconomic analysis of physiotens in patientswith arterial hypertension, overweight and type 2 diabetes mellitusin framework of Russian Public Health System
Author(s) -
A.Yu. Kulikov
Publication year - 2009
Publication title -
ožirenie i metabolizm
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.154
H-Index - 5
eISSN - 2306-5524
pISSN - 2071-8713
DOI - 10.14341/2071-8713-5245
Subject(s) - moxonidine , medicine , overweight , diabetes mellitus , type 2 diabetes mellitus , stroke (engine) , type 2 diabetes , intensive care medicine , obesity , health care , public health , emergency medicine , endocrinology , nursing , agonist , mechanical engineering , receptor , engineering , economic growth , economics
The present article represent a pharmacoeconomic comparison of standard antihypertensive therapy and the same therapy plus moxonidine (Physiotens) in patients with arterial hypertension, overweight and diabetes mellitus type 2. The budget impact analysis was conducted on outpatient and inpatient care basis. Moxonidine showеd convincing advantages compared to standard antihypertensive therapy such as the stroke risk reduction by 6 percent, reduction of doses antihypertensive and hypoglycemic drugs, which resulted in substantial decrease of direct medical costs.